These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 21961848)

  • 1. An assessment of the health and economic burdens of glaucoma.
    Varma R; Lee PP; Goldberg I; Kotak S
    Am J Ophthalmol; 2011 Oct; 152(4):515-22. PubMed ID: 21961848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine eye examinations for persons 20-64 years of age: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(15):1-81. PubMed ID: 23074485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study.
    Kymes SM; Kass MA; Anderson DR; Miller JP; Gordon MO;
    Am J Ophthalmol; 2006 Jun; 141(6):997-1008. PubMed ID: 16765666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the lifetime economic consequences of glaucoma in France.
    Philippe Nordmann J; Lafuma A; Berdeaux G
    J Med Econ; 2009 Mar; 12(1):9-16. PubMed ID: 19450060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.
    Lee PP; Walt JG; Doyle JJ; Kotak SV; Evans SJ; Budenz DL; Chen PP; Coleman AL; Feldman RM; Jampel HD; Katz LJ; Mills RP; Myers JS; Noecker RJ; Piltz-Seymour JR; Ritch RR; Schacknow PN; Serle JB; Trick GL
    Arch Ophthalmol; 2006 Jan; 124(1):12-9. PubMed ID: 16401779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [On the socio-economic relevance of glaucoma].
    Grüb M; Rohrbach JM
    Klin Monbl Augenheilkd; 2006 Oct; 223(10):793-5. PubMed ID: 17063419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands.
    Oostenbrink JB; Rutten-van Mölken MP; Sluyter-Opdenoordt TS
    J Glaucoma; 2001 Jun; 10(3):184-91. PubMed ID: 11442180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review.
    Rouland JF; Berdeaux G; Lafuma A
    Drugs Aging; 2005; 22(4):315-21. PubMed ID: 15839720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance for ocular hypertension: an evidence synthesis and economic evaluation.
    Burr JM; Botello-Pinzon P; Takwoingi Y; Hernández R; Vazquez-Montes M; Elders A; Asaoka R; Banister K; van der Schoot J; Fraser C; King A; Lemij H; Sanders R; Vernon S; Tuulonen A; Kotecha A; Glasziou P; Garway-Heath D; Crabb D; Vale L; Azuara-Blanco A; Perera R; Ryan M; Deeks J; Cook J
    Health Technol Assess; 2012 Jun; 16(29):1-271, iii-iv. PubMed ID: 22687263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic impact of sight loss and blindness in the UK adult population.
    Pezzullo L; Streatfeild J; Simkiss P; Shickle D
    BMC Health Serv Res; 2018 Jan; 18(1):63. PubMed ID: 29382329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is more always better?
    Tuulonen A
    Acta Ophthalmol Scand; 2004 Aug; 82(4):377-9. PubMed ID: 15291927
    [No Abstract]   [Full Text] [Related]  

  • 12. How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications.
    De Natale R; Draghi E; Dorigo MT
    Acta Ophthalmol Scand; 2004 Aug; 82(4):393-6. PubMed ID: 15291930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effective evaluation of the glaucoma suspect.
    Doshi A; Singh K
    Curr Opin Ophthalmol; 2007 Mar; 18(2):97-103. PubMed ID: 17301609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health economics, economic evaluation, and glaucoma.
    Kobelt G
    J Glaucoma; 2002 Dec; 11(6):531-9. PubMed ID: 12483101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches.
    Orme M; Collins S; Loftus J
    J Glaucoma; 2012 Sep; 21(7):433-49. PubMed ID: 21677590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk assessment in the management of patients with ocular hypertension.
    Weinreb RN; Friedman DS; Fechtner RD; Cioffi GA; Coleman AL; Girkin CA; Liebmann JM; Singh K; Wilson MR; Wilson R; Kannel WB
    Am J Ophthalmol; 2004 Sep; 138(3):458-67. PubMed ID: 15364230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic impact of primary open-angle glaucoma in Australia.
    Dirani M; Crowston JG; Taylor PS; Moore PT; Rogers S; Pezzullo ML; Keeffe JE; Taylor HR
    Clin Exp Ophthalmol; 2011; 39(7):623-32. PubMed ID: 21631669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT.
    Gazzard G; Konstantakopoulou E; Garway-Heath D; Garg A; Vickerstaff V; Hunter R; Ambler G; Bunce C; Wormald R; Nathwani N; Barton K; Rubin G; Morris S; Buszewicz M
    Health Technol Assess; 2019 Jun; 23(31):1-102. PubMed ID: 31264958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of glaucoma interventions in Barbados and Ghana.
    Wittenborn JS; Rein DB
    Optom Vis Sci; 2011 Jan; 88(1):155-63. PubMed ID: 21076360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany.
    Kobelt G; Jönsson L; Gerdtham U; Krieglstein GK
    Graefes Arch Clin Exp Ophthalmol; 1998 Nov; 236(11):811-21. PubMed ID: 9825256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.